GenSight is developing ophthalmic therapeutics using gene therapy. The company is focused on a gene replacement therapy for Leber’s hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa. GenSight's lead product is in clinical trials in LHON patients. The company went public in July 2016.

Location Paris, France
CEO Bernard Gilly
Partner Genghis Lloyd-Harris
Website www.gensight-biologics.com